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IntroductIon
The coagulation cascade represents an evolutionary highly 
conserved process that enables efficient hemostasis in response 
to vascular injury. However, an aberrant intravascular activa-
tion of the coagulation cascade causes thrombotic disease, in-
cluding myocardial infarction, ischemic stroke, or deep-venous 
thrombosis, and thus represents the leading cause of death 
worldwide (Stevens et al., 2009). Both hemostasis and throm-
bosis involve the initial formation of a yet unstable platelet 
aggregate at the site of vascular injury (Wolberg, 2007). The 
subsequent activation of plasmatic coagulation results in the 
formation and polymerization of fibrin, an insoluble protein 
Blood coagulation is essential for physiological hemostasis but simultaneously contributes to thrombotic disease. However, 
molecular and cellular events controlling initiation and propagation of coagulation are still incompletely understood. In this 
study, we demonstrate an unexpected role of eosinophils during plasmatic coagulation, hemostasis, and thrombosis. using a 
large-scale epidemiological approach, we identified eosinophil cationic protein as an independent and predictive risk factor for 
thrombotic events in humans. concurrent experiments showed that eosinophils contributed to intravascular thrombosis by 
exhibiting a strong endogenous thrombin-generation capacity that relied on the enzymatic generation and active provision of 
a procoagulant phospholipid surface enriched in 12/15-lipoxygenase–derived hydroxyeicosatetraenoic acid–phosphatidyleth-
anolamines. our findings reveal a previously unrecognized role of eosinophils and enzymatic lipid oxidation as regulatory ele-
ments that facilitate both hemostasis and thrombosis in response to vascular injury, thus identifying promising new targets for 
the treatment of thrombotic disease.
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that allows growth and stabilization of the developing throm-
bus. Initiation of the coagulation cascade essentially relies on 
the presence of a procoagulant phospholipid surface and the 
glycoprotein tissue factor (TF; Nemerson, 1968). These two 
components initiate the sequential assembly and activation 
of the membrane-associated prothrombinase complex (fac-
tor Xa [FXa] and factor Va; Nemerson, 1968), which gener-
ates thrombin, the serine protease that converts fibrinogen 
to fibrin, and thereby provides the backbone of the growing 
thrombus (Wolberg, 2007).
Although all cellular membranes contain abundant 
amounts of phospholipids, they are usually inert and do 
not support coagulation. Platelets are considered to serve 
as a major source of procoagulant phospholipids, as these 
cells can actively modify their membrane and oxidize and 
externalize the aminophospholipids phosphatidylethanol-
amine (PE) and phosphatidylserine (PS; Suzuki et al., 2010; 
Thomas et al., 2010; Yang et al., 2012; O’Donnell et al., 2014). 
Although platelets can potentially acquire TF via leuko-
cyte-derived microparticles, they lack endogenous expression 
of TF (Bouchard et al., 2010). These findings raise the ques-
tion about the exact mechanisms and cells that initiate the 
assembly of the prothrombinase complex during the onset of 
coagulation and the propagation of intravascular thrombo-
sis (Flaumenhaft, 2014).
Here, we report that thrombotic events in humans 
are associated with an in increase in the eosinophilic acti-
vation marker eosinophilic cationic protein (ECP). Subse-
quent experiments showed that eosinophils were abundantly 
found in thrombi that formed upon vascular injury in mice, 
where these cells critically contributed to thrombin forma-
tion and thrombus stabilization as well as to physiological 
hemostasis. Eosinophils exerted a strong endogenous throm-
bin-generation capacity that relied on the simultaneous 
expression of TF and the provision of a procoagulant phos-
pholipid surface that was enriched in 12/15-lipoxygenase 
(12/15-LO)–derived oxidized phospholipids. In accordance, 
we observed a diminished thrombus formation and defective 
hemostatic response in mice carrying a global or an eosino-
phil-specific deletion of 12/15-LO.
results
elevation of eosinophil activation markers predicts  
the onset of cardiovascular events
To elucidate mechanisms that trigger thrombotic events 
during cardiovascular disease (CVD) in humans, we made use 
of the prospective population-based Bruneck Study (Stege-
mann et al., 2014). Population characteristics are summarized 
in Table S1. This study allows unique monitoring of athero-
sclerosis progression and differentiates between early athero-
sclerosis, advanced atherosclerotic lesions, and the occurrence 
of thrombotic events such as stroke and myocardial infarction. 
In contrast to early atherosclerosis, which primarily reflects 
a chronic inflammatory intima thickening, both develop-
ment of advanced atherosclerotic lesions and especially the 
occurrence of thrombotic events are primarily associated 
with factors reflecting enhanced plaque vulnerability and a 
procoagulant state (Willeit et al., 2000). Therefore, we sought 
to identify novel serologic markers that specifically pre-
dict the occurrence of advanced atherosclerotic lesions and 
thrombotic events. A proteomic proximity ligation assay un-
expectedly identified an increased plasma level of ECP as a 
highly significant predictor of new-onset atherothrombotic 
events and development of advanced atherosclerotic lesions 
(Fig. 1, A and B). In contrast, ECP levels were unrelated to 
early plaque development and growth and showed only weak 
correlations with age and other vascular risk factors (Fig. 1, 
B–D). These findings were robust to multivariable adjustment 
and stable in sensitivity analyses (Fig. 1, C and D). Because 
plasma ECP levels serve as a potential marker for eosinophil 
activation, these data were suggestive of a contribution of eo-
sinophils to thrombus formation and vessel occlusion.
eosinophils promote intravascular thrombin 
formation and thrombus growth
Immunofluorescence microscopy of experimentally induced 
thrombi indeed confirmed enrichment of eosinophils, which 
accumulated at the boarder of platelet-rich areas throughout 
the thrombus (Fig. 2, A and B; and Fig. S1, A–E). To deter-
mine whether eosinophils actively contributed to the forma-
tion of an intravascular thrombus, we consequently performed 
an injury-induced venous thrombosis model of the inferior 
venae cava (IVC) in two different eosinophil-deficient mouse 
strains, namely ΔdblGATA1 mice (Yu et al., 2002) and PHIL 
mice (Lee et al., 2004), as well as in their WT littermates. 
Absence of eosinophils resulted in a dramatically attenuated 
thrombus formation (Fig.  2, C and D), which supported a 
functional contribution of these cells. Also, WT mice that 
had received an eosinophil-depleting anti-SiglecF anti-
body showed a significantly decreased thrombotic potential 
(Fig. 2 E and Fig. S1 F).
As these data pointed toward a so far unrecognized role 
of eosinophils during the initiation and/or propagation of 
thrombosis, we sought to elucidate the underlying mecha-
nisms. We did not observe alterations in platelet numbers or 
platelet function or any intrinsic defects of clotting factors in 
eosinophil-deficient mice (Fig. S2, A–C). However, measure-
ment of plasmatic thrombin–antithrombin (TAT) complexes 
as a quantitative marker for thrombin generation showed that 
TAT complexes rapidly appeared after induction of thrombo-
sis in WT mice but were almost absent in eosinophil-deficient 
mice (Fig. 2 F). These data were indicative of a major contri-
bution of eosinophils to the initiation of plasmatic coagula-
tion and the intravascular generation of thrombin in response 
to vascular injury. As thrombin-mediated blood coagulation is 
considered essential for the stabilization of the initial platelet 
aggregate and thrombus growth (Wolberg, 2007), we conse-
quently used intravital video microscopy to visualize platelet 
aggregation and thrombus formation upon vascular injury 
in the mouse carotid artery of WT and eosinophil-deficient 
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Figure 1. elevation of ecP serves as a marker for cVd in humans. (A and B) Forest plots of the prospective association of baseline ECP with events of 
CVD (A) and early and advanced atherosclerosis (B) in the Bruneck Study (follow-up 2000 to 2010). All analyses were adjusted for age, sex, and prior CVD. 
Analyses focusing on ultrasound endpoints were adjusted to the extent of baseline atherosclerosis (log-transformed atherosclerosis summation score). 
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mice. Whereas an absence of eosinophils did not impair the 
formation of a first platelet-rich aggregate at the site of in-
jury, it provoked a rapid dissolution of this yet unstable ini-
tial thrombus (Fig. 2 G and Videos 1–4). In line with these 
findings, we observed an exacerbated blood loss in eosino-
phil-deficient ΔdblGATA1 mice after a medium-scale injury 
(15-mm tail cut; Fig. 2 H), indicative of a defective coagu-
lation-dependent secondary hemostasis. Platelet-dependent 
primary hemostasis after small-scale injury (3-mm tail cut) 
was unaffected by the absence of eosinophils (Fig. S2 D). 
Platelet depletion, in turn, unmasked the defective hemostasis 
in ΔdblGATA1 mice after the small-scale injury, which was 
depicted by a dramatically augmented blood loss (Fig. S2, E 
and F) and, thus, demonstrated that platelets and eosinophils 
performed synergistic roles during thrombosis and hemosta-
sis. Notably, absence of eosinophils did not impair thrombus 
development in the IVC upon flow restriction (Fig. S2 G), 
suggesting that this leukocyte subset specifically mediated the 
hemostatic and thrombotic response upon vascular injury but 
did not contribute to stasis-induced thrombus formation.
eosinophils autonomously generate thrombin 
in a tF-dependent manner
Together, our data revealed a key role of eosinophils during 
injury-induced thrombin generation and blood coagulation 
in vivo. Consequently, we determined whether these cells 
were able to autonomously generate thrombin in the absence 
of exogenous procoagulant phospholipids or recombinant TF. 
We found that in vitro–differentiated mouse eosinophils as 
well as isolated human eosinophils indeed exerted a dramatic 
endogenous thrombin generation potential, which was fur-
ther augmented by prestimulation of eosinophils with ADP or 
collagen (Fig. 3, A and B). Thrombin generation was preceded 
by formation of FXa and followed by the appearance of fibrin 
clots (Fig. 3, C and D; and Fig. S3 A). These data indicated the 
involvement of a TF-dependent pathway and suggested that 
eosinophils were equipped with all the necessary key compo-
nents for the initiation of plasmatic coagulation, which would 
include an endogenous provision of TF and procoagulant 
phospholipids. We confirmed expression of TF by eosinophils, 
which were additionally able to expose this glycoprotein on 
their surface upon ADP stimulation (Fig. 3, E and F; and Fig. 
S3 B). Addition of a blocking antibody against TF abrogated 
eosinophil-induced thrombin generation, confirming the 
functional involvement of this glycoprotein (Fig. 3 G).
eosinophils actively provide a procoagulant phospholipid 
surface that supports tF-mediated thrombin generation
The thrombin generation potential of activated eosino-
phils was clearly superior to other TF-expressing cells, such 
as LPS-stimulated macrophages (Fig. S3 C). These findings 
suggested that additional factors allowed eosinophils to effi-
ciently promote coagulation. As the TF-mediated generation 
of thrombin is considered to depend on the presence of a pro-
coagulant phospholipid surface (Nemerson, 1968; Mackman, 
2004), we determined whether eosinophils underwent spe-
cific changes within their plasma membrane that would sup-
port plasmatic coagulation. The aminophospholipids PS and 
PE can facilitate thrombin generation but are usually hidden 
within the inner leaflet of the plasma membrane and, thus, 
are unavailable for an interaction with plasmatic coagulation 
factors (Thomas et al., 2010; Yang et al., 2012). Measurement 
of annexin V surface binding, a surrogate marker for the ex-
posure of aminophospholipids (Clark et al., 2013), revealed 
a rapid increase in the annexin V positivity of eosinophils in 
response to ADP, indicating that these cells actively changed 
the polarity of their plasma membrane (Fig. 4 A). Exposure 
of PE and PS species was additionally confirmed using mass 
spectrometry (Fig. 4 B). However, masking of surface ami-
nophospholipids by annexin V blocked the ADP-induced 
thrombin generation in a dose-dependent manner (Fig. 4 C), 
confirming an essential role of these events during eosino-
phil-induced coagulation.
In platelets, translocation of PS and PE was shown to 
involve the activity of Ca2+-sensitive Cl− channels of the 
TMEM (transmembrane protein) gene family, which were 
suggested to additionally control cationic currents and seem 
to either possess or induce scramblase activity at the plasma 
Squares and lines represent hazard ratios of events and 95% confidence intervals (CI). Hazard ratios were derived from Cox regression models and calculated 
for a 1-SD–higher level of ECP. Composite CVD events considered ischemic strokes, medical record–confirmed TIAs, myocardial infarctions, and vascular 
deaths. Mean and median follow-ups were 8.6 and 10 yr. The extended CVD events additionally considered revascularization procedures. *, This analysis is 
confined to 277 individuals free of atherosclerosis at baseline and focused on the manifestation of first carotid plaques. †, This analysis considers all 558 in-
dividuals with ultrasound follow-up and focused on the manifestation of new carotid plaques. ‡, This analysis considers all 558 individuals with ultrasound 
follow-up and focused on both the manifestation of new carotid plaques and extension of existing ones. §, This analysis considers all 558 individuals with 
ultrasound follow-up and focused on the development of advanced complicated plaques (stenosis >40%). The second line is confined to 269 subjects with 
manifest baseline atherosclerosis. (C) Odds ratios/hazard ratios and 95% confidence intervals derived from logistic regression and Cox regression models 
and calculated for a 1-SD–higher level of ECP. The composite CVD endpoint included ischemic strokes, medical record–confirmed TIAs, myocardial infarc-
tions, and vascular deaths. *, Multivariable models were additionally adjusted for hypertension, smoking (pack-years), diabetes, log-transformed C-reactive 
protein, body-mass index, and LDL and HDL cholesterol. †, Models with extended adjustment additionally included HbA1c, platelet, and lymphocyte counts. 
(D) Correlation pattern of ECP level with blood cell counts and demographic and vascular risk factors in the Bruneck Study (evaluation 2000; n = 682 
including 354 women and 328 men). BP, blood pressure; GFR, glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-C, HDL cholesterol; hs-CRP, 
high-sensitivity C-reactive protein; LDL-C, LDL cholesterol. Spearman correlation coefficients are given for all variables. Correlations that are statistically 
significant after correction for multiple comparisons (Bonferroni-corrected p-value <0.05) are in bold, and corresponding squares have covering colors.
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membrane (Suzuki et al., 2010; Tian et al., 2012; Yang et al., 
2012; Kunzelmann et al., 2014). Also, eosinophils expressed 
several TMEM family members (Fig. S3 D), and the Ca2+ 
ionophore A23187 rapidly triggered exposure of the ami-
nophospholipids PE and PS in eosinophils (Fig. 4 D and Fig. 
S3 E). Intracellular chelation of Ca2+ by BAP TA/AM or ad-
dition of tannic acid, a nonselective inhibitor of the TMEM 
family of calcium-activated Cl− channels, in turn, interfered 
with the ADP-induced binding of annexin V to their sur-
face (Fig.  4  E). In line with these findings, ADP stimula-
tion of eosinophils triggered a rapid and transient increase 
in cytosolic Ca2+ levels in a Ca2+-free environment, which 
could be boosted by the addition of extracellular calcium 
(Fig. 4 F). Prior depletion of intracellular calcium stores by 
thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+ 
ATPase, blocked the initial ADP-induced increase in cyto-
solic Ca2+ (Fig. 4 G). These data were suggestive of an ini-
tial ADP-induced Ca2+ release from intracellular stores and 
a subsequent activation of a store-operated calcium entry 
through the plasma membrane (Bergmeier et al., 2013) that 
triggered exposure of procoagulant aminophospholipids to 
immediately support TF-dependent formation of the pro-
thrombin complex (Fig. 4 H).
12/15-lo–mediated formation of procoagulant 
oxidized phospholipids essentially contributes to the 
thrombin-generation potential of eosinophils
Next, we aimed to determine whether specific aminophospho-
lipid species accounted for the increased thrombin-generation 
potential of eosinophils and performed an additional lipid-
omic analysis of their phospholipid profile, which showed that 
their cellular membranes were enriched in a specific set of 
Figure 2. eosinophils contribute to intravascular thrombosis and hemostasis. (A) Representative microscopy image (n = 5) showing immunoflu-
orescence staining for platelets (CD41; green), eosinophils (CCR3; red), and cellular nuclei (DAPI; blue) in a ferric chloride (FeCl)–induced thrombus of a 
mouse IVC. White arrowheads indicate CCR3+ eosinophils, and dashed lines mark lacunae surrounded by platelet aggregates. Bar, 100 µm. (B) Relative 
number of eosinophils in IVC thrombi of WT mice compared with peripheral blood counts. n = 5. (C and D) FeCl-induced IVC thrombus of ΔdblGATA1 
mice (BALB/c background; n = 4; C), PHIL mice (C57BL/6 background; n = 10; D), and their corresponding WT littermates. Bar, 2 mm. (E) FeCl-induced IVC 
thrombosis in WT mice treated with anti-SiglecF antibody (n = 4) or isotope control. (F) Measurement of TAT complexes in plasma from dblGATA1 mice (n = 
5) after FeCl-induced IVC thrombosis. (G) Representative image of a FeCl-induced thrombosis of the carotid artery in WT or ΔdblGATA1 mice (30 min after 
FeCl-induced injury) and quantification of the kinetics of thrombus formation and dissolution (right; see also supplementary videos). n = 4. Bars, 200 µm. 
(H) Bleeding assays (15-mm tail cut) with WT (BALB/c; n = 5) and ΔdblGATA1 mice (n = 9). Bar graphs show relative weight loss, OD575nm of the lost blood 
after lysis, and primary bleeding time (time until the first stop of bleeding). Data are representative of at least three independent experiments. Error bars 
represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; Student’s t test.
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PE oxidation products (12–hydroxyeicosatetraenoic acid–PEs 
[12-HETE-PEs]; Fig.  5  A). As oxidation of phospholipids 
had been suggested to increase their procoagulant potential 
(Thomas et al., 2010), we sought to determine a potential role 
of PE oxidation and the different oxidized PE species during 
eosinophil-mediated thrombin generation. 12-LO (Alox12) 
and 12/15-LO (Alox15) are the two major enzymes exert-
ing 12-LO activity in mammals (Kuhn et al., 2015) and thus 
served as the potential enzymatic source for the identified 
12-HETE-PEs in eosinophils. Analysis of peripheral blood 
leukocytes and platelets showed that Alox12 was absent in all 
leukocyte subsets and exclusively expressed in platelets. Alox15 
mRNA and 12/15-LO protein, in turn, were highly expressed 
in mouse and human eosinophils but absent in platelets, mono-
cytes, neutrophils, and the healthy vascular wall (Fig. 5, B–D; 
and Fig. S3 F). These data showed that, during the steady state, 
Figure 3. eosinophils autonomously initiate thrombin generation. (A and B) Calibrated thrombin generation curve of in vitro–generated mouse eo-
sinophils (mEOS; A) or human eosinophils (huEOS; B) after stimulation with ADP and/or collagen. Bar graphs show endogenous thrombin potential (ETP; 
nM*min) and peak of thrombin generation (peak; nM). (C) Calibrated FXa generation curve of mouse eosinophils. AU, arbitrary units. (D) Plasma clotting 
time experiments with in vitro–generated mouse eosinophils (Eos) stimulated with ADP or collagen. Bar graphs display calculated clotting index. The black 
bar shows plasma with ADP alone. (E, left) Quantitative RT-PCR analysis of TF mRNA (F3) expression in mouse monocytes (monos), neutrophils (PMN), 
eosinophils (eos), and platelets (plts); expression of the gene of interest was normalized to Atcb expression. (Right) Western blot analysis of TF protein (47 
kD) expression in sorted mouse leukocytes. (F) Flow cytometry analysis of the exposure of TF on the surface of resting or ADP-stimulated mouse eosinophils. 
Histograms show representative flow cytometric stainings, and bar graphs show mean geometric fluorescence intensities (geom. MFI). (G, left) Calibrated 
thrombin generation assay with ADP-stimulated mouse eosinophils in the presence of blocking anti-TF antibody or isotope control. (Right) Bar graphs show 
endogenous thrombin potential (ETP; nM*min) and peak of thrombin generation (peak; nM). Data are representative of at least three independent experi-
ments. Error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; Student’s t test.
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eosinophils were the only cells expressing Alox15 within the 
peripheral blood and the vasculature. 12/15-LO expression 
was accordingly absent in blood leukocytes of 12/15-LO– 
deficient (Alox15−/−) and eosinophil-deficient ΔdblGATA1 
mice (Fig. 5, E and F). Mass spectrometry showed that Alox15−/− 
eosinophils indeed lacked the identified 12-HETE-PEs, thus 
confirming 12/15-LO as the single enzymatic source of these 
oxidized aminophospholipids in eosinophils (Fig. 5 G).
Figure 4. ca2+-dependent exposure of aminophospholipids by eosinophils promote thrombin generation. (A) Flow cytometry analysis of the bind-
ing of annexin V (AxV) to aminophospholipids on the surface of resting or ADP-stimulated mouse eosinophils. Histograms show representative annexin 
V stainings, and bar graphs show mean geometric fluorescence intensities (gMFI). (B) LC/MS/MS-based quantification of the exposure of the aminophos-
pholipids PE and PS in mouse eosinophils in response to ADP stimulation. (C, left) Calibrated thrombin generation assays with resting or ADP-stimulated 
mouse eosinophils in the presence of annexin V. (Right) Bar graphs show endogenous thrombin potential (ETP; nM*min) and peak of thrombin generation 
(peak; nM). (D) Flow cytometry analysis of annexin V binding on mouse eosinophils over time in the presence of calcium ionophore A23187, ADP, or vehicle. 
(E) Flow cytometry analysis of annexin V binding on mouse eosinophils in the presence of tannic acid (TA) or intracellular Ca2+-chelator BAP TA/AM. Bar 
graphs show geometric mean fluorescence intensity. (F) Flow cytometry–based analysis of intracellular Ca2+ signaling, indicated by Fluo3/FuraRed ratio, over 
time in a Ca2+-free environment. Where indicated (arrow and Ca2+), CaCl2 at a final concentration of 1 mM was added. (G) Flow cytometry–based analysis 
of intracellular Ca2+ signaling, indicated by Fluo3/FuraRed ratio, over time in a Ca2+-free environment. (H) Postulated mechanism of a sequential generation 
and Ca2+-dependent externalization of aminophospholipids (APL) at the surface of eosinophils. OH indicates hydroxyl group. Data are representative of at 
least three independent experiments. Error bars represent SEM. *, P < 0.05; ***, P < 0.001.
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Figure 5. 12/15-lo–mediated oxidation of membrane phospholipids initiates eosinophil-mediated thrombin formation. (A) Representative LC/
MS/MS analysis of different 12-HETE-PE oxidation species in lipid extracts of in vitro–generated mouse eosinophils. Cps, counts per second. (B) Quantitative 
RT-PCR analysis of 12/15-LO mRNA (Alox15) and 12-LO mRNA (Alox12) in mouse monocytes (monos; CD11b+CD115+), neutrophils (PMN; CD11b+Ly6G+), 
2129JEM Vol. 214, No. 7
In accordance with a major contribution of 12/15-LO–
mediated membrane oxidation to the thrombin-formation 
activity of eosinophils, we observed a severely reduced abil-
ity of Alox15−/− eosinophils to generate thrombin and FXa 
as well as to induce fibrin clots (Fig.  5, H and I; and Fig. 
S3 G). The 12/15-LO inhibitor baicalein potently interfered 
with the procoagulant activity of mouse and human eosino-
phils as well (Fig. 5, H–J), showing that the Alox15-mediated 
control of plasma coagulation by eosinophils represented an 
evolutionary conserved mechanism and potential target for 
pharmacologic intervention during thrombotic disease. Of 
note, 12/15-LO–deficient eosinophils showed no alterations 
in their eosinophil maturation markers (Fig. S3, H and I). 
Phospholipase A2 (PLA2)–dependent cleavage of 12/15-LO 
products from membrane phospholipids was not involved in 
the 12/15-LO–mediated thrombin generation activity of eo-
sinophils, as inhibition of PLA2 activity did not reduce the 
procoagulant activity of eosinophils (Fig. S3 J).
We subsequently measured thrombin generation in 
the presence of liposomes containing different PE species to 
substitute for 12/15-LO activity. Addition of liposomes with 
12-HETE-PE immediately restored the thrombin-generation 
potential of Alox15−/− eosinophils, whereas identical lipo-
somes with nonoxidized PEs were ineffective (Fig.  5  K), 
supporting the concept of a 12/15-LO–mediated control of 
thrombin generation that was dependent on generation and 
provision of 12-HETE-PEs.
12/15-lo expression in eosinophils promotes thrombotic 
disease and supports physiological hemostasis
To determine the in vivo relevance of 12/15-LO–mediated 
membrane oxidation by eosinophils during thrombotic dis-
ease, we performed an injury-induced thrombosis model in 
Alox15−/− mice and their WT littermates. In line with our 
previous data, absence of 12/15-LO resulted in reduced TAT 
complex formation (Fig. 6 A) and an impaired thrombus for-
mation (Fig.  6  B). Alox15−/− mice accordingly displayed a 
defective hemostatic response (Fig. 6 C), although these an-
imals showed no alterations in the function and number of 
platelets or in plasmatic coagulation factors (Fig. S4, A–C). We 
subsequently confirmed a reduced thrombotic potential of 
mice carrying a conditional deletion of Alox15 in eosinophils 
as well as in animals that had received baicalein, demonstrat-
ing a key role of the identified pathway during coagula-
tion in vivo and highlighting its potential as a therapeutic 
target (Fig. 6, D and E).
dIscussIon
Until recently, eosinophils were solely envisaged as driving 
force of parasite defense and as mediators of allergic disease 
(Jacobsen et al., 2012). However, an increasing amount of data 
suggests a broader and rather homeostatic role of these cells 
during the resolution of inflammation and regulation of tis-
sue repair (Rothenberg and Hogan, 2006; Lee et al., 2010; 
Heredia et al., 2013; Tani et al., 2014). More recently, eosin-
ophils were also described to accumulate in human thrombi 
(Riegger et al., 2016) and reported to express TF (Moosbauer 
et al., 2007). Moreover, activated eosinophils were shown to 
tether to immobilized platelets under shear flow (McCarty et 
al., 2003), a mechanism which might explain their homing 
to the freshly formed and yet instable thrombus. Clinical data 
show that hypereosinophilic patients indeed suffer from an 
increased incidence of atypical thrombotic events (Ames et 
al., 2010; Todd et al., 2014). Although these findings have indi-
cated a potential role of this leukocyte subset during thrombus 
formation, functional evidence that supports a direct contri-
bution of eosinophils to thrombosis or hemostasis as well as 
insights into involved molecular pathways have been lacking 
so far. Our current data show that eosinophils critically con-
tribute to thrombin formation and plasmatic coagulation, a 
process that is often regarded as the most primitive form of 
immune response to tissue injury and infection (Engelmann 
and Massberg, 2013). Other leukocyte subsets have been pre-
viously implicated as potential sources of TF and might like-
wise contribute to thrombus formation in certain settings (von 
Brühl et al., 2012; Engelmann and Massberg, 2013). However, 
eosinophils (eos; side scatterhiCD11b+Siglec-F+), and platelets (plts) after FACS. Expression was normalized to Atcb expression. rel., relative. (C) Western blot 
of 12/15-LO protein (74 kD) expression in WT and Alox15−/− mouse eosinophils. (D) Quantitative RT-PCR analysis of Alox5 and Alox15 mRNA (top) and West-
ern blot analysis of 15-LO protein (bottom) expression in human neutrophils (huPMN) and human eosinophils (huEos) isolated by Ficoll density gradient 
centrifugation and magnetic cell separation. mRNA expression was normalized to Actb. (E) Flow cytometry analysis of 12/15-LO in eosinophils (side scat-
terhiSiglecF+) isolated from peripheral blood of WT and Alox15−/− mice. (F) Flow cytometry analysis of the side scatter (SSC)hi12/15-LO+ population in blood 
from WT, Alox15−/−, and ΔdblGATA1 mice. (G) LC/MS/MS-based quantification of different esterified 12- and 15-HETE-PE, nonesterified 5-, 8-, 11-, 12-, and 
15-HETE species, and prostaglandins D2 and E2 (PGD2 and PGE2) in WT (blue) and Alox15−/− (red) mouse eosinophils. Levels are presented as nanograms 
per 106 cells. (H, left) Calibrated thrombin generation curve of mouse WT eosinophils, eosinophils treated with baicalein (Bai), and Alox15−/− eosinophils. 
(Right) Bar graphs show endogenous thrombin potential (ETP; nM*min) and peak of thrombin generation (peak; nM). (I) Plasmatic clotting time experiments 
with WT mouse eosinophils (EOS), mouse eosinophils treated with the 12/15-LO inhibitor baicalein, and Alox15−/− mouse eosinophils. Bar graphs display 
calculated clotting index. The black bar shows plasma with ADP alone. (J, left) Calibrated thrombin generation assay with lysates generated from human 
eosinophils in the presence of PRP reagent (see Materials and methods). (Right) Bar graphs show endogenous thrombin potential (nM*min) and peak of 
thrombin generation (nM). (K, left) Calibrated thrombin generation assays with WT and Alox15−/− mouse eosinophils in the presence of phosphatidylcho-
line/PS liposomes carrying oxidized 12-HETE-PE or nonoxidized PE (SAPE) species, as indicated. (Right) Bar graphs show endogenous thrombin potential 
(nM*min) and peak of thrombin generation (nM). Data are representative of at least three independent experiments. Error bars represent SEM. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001; Student’s t test.
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neutrophils and monocytes in the peripheral blood seem to be 
unable to provide an enzymatically engineered, procoagulant 
phospholipid surface, whereas platelets express prothrombotic 
phospholipids but lack intrinsic TF expression. Thus, eosin-
ophils seem to combine the abilities of platelets to oxidize 
and expose distinct prothrombotic aminophospholipids with 
the capacity of leukocytes to provide TF within a single cell 
(Fig. 6 F). Notably, neutrophils were shown to contribute to 
stasis-induced thrombosis but were fully dispensable during 
hemostasis after vascular injury (Engelmann and Massberg, 
2013). Eosinophils, in turn, seem to primarily mediate the 
hemostatic and thrombotic response that follows tissue injury, 
suggesting that different leukocyte subsets fulfill distinct tasks 
during hemostasis and thrombosis.
On a molecular level, we identify mouse 12/15-LO 
and its human orthologue 15-LO as key enzymes during 
the generation of procoagulant phospholipids in eosin-
ophils and show that this pathway directly contributes to 
the initiation of thrombus formation after injury. Although 
12/15-LO expression in macrophage-derived foam cells has 
been previously implicated in the oxidation of low-density 
lipoprotein (LDL) particles and the formation of athero-
sclerotic plaques (Cyrus et al., 2001; Uderhardt and Krönke, 
2012), the physiological role of 12/15-LO–mediated lipid 
oxidation has remained unclear (Kühn and O’Donnell, 
2006). Our findings suggest that 12/15-LO–mediated enzy-
matic lipid oxidation serves as a key mechanism controlling 
eosinophil-directed coagulation and physiological hemosta-
sis. Thus, our current data provide an explanation for the 
stringent conservation of this enzymatic pathway during 
mammalian evolution and simultaneously suggest that eo-
sinophils as well as 12/15-LO are promising new targets for 
an anticoagulant therapy.
MaterIal and MetHods
Patient cohorts
Bruneck study population. The Bruneck Study is a prospec-
tive population-based survey on the epidemiology and patho-
Figure 6. 12/15-lo–induced coagulation contributes to thrombus formation and hemostasis. (A and B) TAT complex formation (n = 6; A) and 
thrombus formation (n = 4; B) after ferric chloride (FeCl)–induced thrombosis of the IVC in Alox15−/− mice (C57BL/6 background) and WT littermates. 
(C) Bleeding assays (15-mm tail cut) with WT (C57BL/6) mice, Alox15−/− mice, and WT mice treated with baicalein (n = 6 each). Bar graphs show relative 
weight loss, OD575nm of the lost blood after lysis, and primary bleeding time (time until first stop of bleeding). (D and E) FeCl-induced IVC thrombus forma-
tion in mice carrying an eosinophil-specific deletion of Alox15 (Alox15fl/fl; n = 10) and their WT littermates (Alox15+/+; n = 9; D) and mice that received the 
12/15-LO inhibitor baicalein (n = 4) and a vehicle (n = 4; E). Data are representative of at least three independent experiments. Error bars represent SEM. 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; Student’s t test. (F) Proposed mechanism of the eosinophil-mediated and 12/15-LO–induced thrombin generation in 
response to platelet aggregation.
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genesis of atherosclerosis that started in 1990. The study 
population was recruited as a sex- and age-stratified random 
sample of all residents age 40 to 79 living in Bruneck (n = 
4,739), Northern Italy. Detailed follow up examinations in-
cluding high-resolution ultrasound of the carotid vessels were 
performed every 5 yr. The present analysis focuses on the 
evaluation in 2000 (n = 682 with complete data including 
carotid ultrasound), which served as the baseline for this anal-
ysis, and on the 10-yr follow-up period between 2000 and 
2010. Follow-up for clinical endpoints was 100% complete (n 
= 682, mean and median follow up time 8.6 and 10 yr), 
whereas follow up ultrasound examinations in 2005 and 2010 
were available in 558 men and women (i.e., 91.9% of survi-
vors or 81.8% overall). The study protocol was approved by 
the Ethics Committees of Verona and Bolzano, and all partic-
ipants gave their written informed consent be-
fore entering the study.
All risk factors were assessed by means of validated stan-
dard procedures described previously (Kiechl et al., 2002, 
2013; Stegemann et al., 2014). In brief, body mass index was 
calculated as weight divided by height squared (kg/m2). Hy-
pertension was defined as blood pressure ≥140/90 mm Hg 
(mean of three independent readings obtained with a stan-
dard mercury sphygmomanometer after at least 10 min of 
rest) or the use of antihypertensive drugs. Lifetime smoking 
was assessed as pack-years. Diabetes was defined based on 
American Diabetes Association criteria.
The composite CVD endpoint was composed of isch-
emic stroke, medical record–confirmed transient ischemic at-
tack (TIA), myocardial infarction, and vascular death. A total 
of 102 individuals experienced primary outcome events. The 
extended composite endpoint additionally considered revas-
cularization procedures, which increased the number of in-
dividuals affected to 118. Myocardial infarction was deemed 
confirmed when World Health Organization criteria for defi-
nite disease status were met. Ischemic stroke and TIA were 
classified according to the criteria of the National Survey of 
Stroke. A TIA was considered only if the diagnosis could be 
made with high accuracy (medical record–confirmed TIA). All 
revascularization procedures (angioplasty and surgery) were 
carefully recorded. Ascertainment of events or procedures did 
not rely on hospital discharge codes or the patient’s self-re-
port but on a careful review of medical records provided by 
the general practitioners, death certificates, Bruneck Hospital 
files, and the extensive clinical and laboratory examinations 
performed as part of the study protocols. Major advantages of 
the Bruneck Study are that virtually all subjects living in the 
Bruneck area were referred to the local hospital and that the 
network existing between the local hospital and the general 
practitioners allowed retrieval of practically all medical infor-
mation on persons living in the area. We also collected detailed 
information on the date, causes, and circumstances of death 
for all study subjects who did not survive the entire follow-up 
period by consulting death certificates, all medical records ever 
compiled on study subjects, and autopsy reports in the rare 
event of unexpected death. We were able to ascertain 100% 
of deaths and reliably classify them as vascular deaths, cancer 
deaths, or deaths from other causes (primary cause of death). 
Vascular mortality included deaths from ischemic stroke, myo-
cardial infarction, rupture of aortic aneurysms, and sudden car-
diac deaths. The experienced researcher who categorized all 
deaths and cardiovascular endpoints was unaware of laboratory 
data. There was no loss of follow-up for clinical endpoints.
assessment of atherosclerosis. At each study visit, participants 
underwent bilateral carotid duplex sonography using a 
10-MHz transducer and a 5-MHz Doppler. All subjects were 
examined in supine position. The scanning protocol involved 
four segments of the right and left carotid artery: proximal 
common carotid artery (15–30 mm proximal to the carotid 
bulb), distal common carotid artery (<15 mm proximal to the 
carotid bulb), proximal internal carotid artery (carotid bulb 
and the initial 10 mm of the vessel), and distal internal carotid 
artery (>10 mm above the flow divider). A plaque was de-
fined as a focal structure encroaching into the arterial lumen 
with a thickening of the vessel wall of at least 0.5 mm relative 
to surrounding segments. The maximum axial diameter of 
plaques (in millimeters) was assessed on the near and far walls 
at each of the eight vessel segments. The atherosclerosis sum-
mation score was calculated by summing all diameters (intra- 
observer coefficient of variation, 13.5%; n = 100).
A person-based atherosclerosis progression model 
(Kiechl and Willeit, 1999a; Kiechl et al., 1999b) was devel-
oped and validated in the Bruneck Study that allowed differ-
entiation between early and advanced stages in atherosclerosis 
development (Kiechl et al., 2013). Early atherosclerosis sub-
sumes the manifestation of new plaques and/or nonstenotic 
progression of existing plaques. Main characteristics are a slow 
and continuous plaque growth, usually affecting more than 
one plaque simultaneously and accompanied by a compensa-
tory or even overcompensatory enlargement of the vessel at 
the plaque site. The term incipient atherosclerosis was used for 
the development of first plaques in subjects free of atheroscle-
rosis at baseline (Kiechl et al., 2002). Advanced complicated 
atherosclerosis was assumed when the relative increase in the 
maximum plaque diameter exceeded twice the measurement 
error for the method (internal carotid artery, 25%; common 
carotid artery, 17%) and a lumen narrowing of at least 40% 
was achieved. This process is featured by a usually solitary 
prominent increase in plaque size and absence of vascular 
remodeling, thus resulting in significant lumen compromise. 
From a mechanistic perspective, it refers to plaque destabili-
zation and subsequent atherothrombosis (Willeit et al., 2000).
The two progression categories were highly repro-
ducible (κ coefficients > 0.8 [n = 100]). Risk profiles differ 
significantly between the two stages of carotid artery disease 
with early atherosclerosis relying on standard risk factors and 
advanced atherosclerosis being mainly related to markers re-
flecting plaque vulnerability or enhanced prothrombotic ac-
tivity (Willeit et al., 2000; Kiechl et al., 2007).
Eosinophils promote plasmatic coagulation | Uderhardt et al.2132
statistical methodology. We tested the hypothesis that base-
line ECP level is associated with new-onset CVD and ad-
vanced atherosclerosis (2000–2010), both of which rely on 
atherothrombosis, but not with early atherosclerosis driven by 
inflammation and standard vascular risk factors. Cox propor-
tional hazard models with progressive adjustment were used 
to analyze time-to-event data on the primary CVD endpoint 
(ischemic strokes, medical record–confirmed TIAs, myocar-
dial infarctions, and vascular deaths), extended CVD endpoint 
(plus revascularization procedures), and individual disease 
endpoints (stroke and TIA or myocardial infarction; Fig. 1 A). 
Subjects who suffered a CVD event were censored with re-
spect to subsequent follow-up as were participant who died 
from nonvascular causes. We detected no departure from the 
proportional hazards assumption by inspecting Schoenfeld re-
siduals and checking the parallelism of log–log survival plots. 
Associations between ECP and the various measures of ath-
erosclerosis were tested by means of logistic regression analy-
sis (Fig. 1 B) because the quinquennial examinations in the 
Bruneck Study provide reliable information on plaque devel-
opment/progression in this time interval but no 
time-to-event information.
Base models were adjusted for age, sex, and either prior 
CVD (CVD endpoints) or baseline atherosclerosis (ultrasound 
endpoints). Multivariable analyses were additionally adjusted 
for hypertension, smoking (pack-years), diabetes, loge-trans-
formed C-reactive protein, body-mass index, and LDL and 
high-density lipoprotein (HDL) cholesterol. We modeled 
ECP as a continuous variable and calculated hazard and odds 
ratios for a 1-SD unit–higher level of ECP.
In subsidiary analyses, we excluded subjects with prior 
CVD, eosinophil fractions >5%, or platelet inhibitor therapy. 
All p-values were two sided, and an α level of 0.05 was used. 
Analyses were conducted using SPSS and R 3.2.2 (R Foun-
dation for Statistical Computing).
Proteomic serum analysis. Blood samples were drawn in the 
year 2000 after an overnight fast and 12 h of abstinence from 
smoking and immediately frozen and stored at −70°C (with-
out any thawing-freezing cycle). Laboratory parameters were 
measured by standard assays, and a blood differential was per-
formed using an automated analyzer (Kiechl et al., 2002, 
2013; Stegemann et al., 2014). Eosinophil cationic protein 
(ECP) was measured in plasma samples collected in the year 
2000 as part of a novel proteomics chip (Proximity Extension 
Assay; 4 Proseek Multiplex CVD I96 × 96; Olink Bioscience) 
as described previously (Assarsson et al., 2014).
animals
Animal experiments were approved by the government of 
Mittelfranken, the Mayo Clinic, and the Ludwig Maximil-
ian University, Munich. 12/15-LO–deficient (Alox15−/−; 
C57BL/6 background), ΔdblGata1 (BALB/c background), 
and PHIL mice were described previously (Yu et al., 2002; Lee 
et al., 2004). ΔdblGata1mice carry a deletion of a high-affinity 
GATA-binding site in the GATA-1 promoter (ΔdblGATA-1 
mice), whereas PHIL mice express a diphtheria toxin A trans-
gene that is driven by a fragment of the eosinophil peroxidase 
promoter. Both mouse strains show a selective and complete 
absence of the eosinophilic lineage. To achieve an eosin-
ophil-specific deletion of Alox15, we crossed an EPX-Cre 
mouse (Doyle et al., 2013) with mice carrying floxed Alox15 
alleles (both C57BL/6 background; Cole et al., 2012). Ex-
periments were performed at an age of 8–10 wk. Whereas 
experiments with ΔdblGATA-1 mice were performed in 
hemizygous mutant males and WT male littermates, the ex-
periments with other mouse strains were performed with an 
equal gender distribution of mutant and WT mice. Animal 
experiments were performed by a blinded investigator.
cell culture
Eosinophils were generated from bone marrow isolated from 
8-wk-old mice as previously described (Dyer et al., 2008) 
with minor modifications. In brief, bone marrow was incu-
bated in RPMI medium (Gibco) containing 20% heat-in-
activated feral calf serum (FCS), 25 mM Hepes, 100 IU/ml 
penicillin (Gibco), 10 µg/ml streptomycin (Gibco), 2  mM 
glutamine (Gibco), 1× nonessential amino acids (NEAA; 
Sigma-Aldrich), 1  mM sodium pyruvate (Sigma-Aldrich), 
50  µM β-mercaptoethanol (Gibco), 100 ng/ml mFLT3L 
(PeproTech), and 100 ng/ml mouse stem cell factor (Pepro-
Tech) for 4 d, followed by 10-d differentiation with 10 ng/ml 
IL-5 (PeproTech). Half of the medium was changed every 
other day. Maturation was monitored by flow cytometry of 
SiglecF and CCR3 expression. Fully matured eosinophils 
were used after 14 d of total culture. For thrombin generation 
assays, RAW 264.7 mouse macrophages were treated with 100 
ng/ml LPS in RPMI medium containing 10% FCS for 24 h.
Plasma clotting time
Human standard citrate plasma (Siemens Healthcare) was 
freed from residual cellular and subcellular particles by ul-
tracentrifugation and supplemented with 10% rat plasma 
(GeneTex). Plasma clotting time with or without addition 
of eosinophils was automatically recorded after recalcification 
with 20 µl of star-tem (ROT EM; Tem International GmbH) 
using a ball coagulometer (BC1; SYCOmed) at 37°C. When 
indicated, eosinophils were stimulated with 40  µM ADP 
(Roche) or 20 µg/ml collagen (Roche) for 10 min at 37°C 
before recalcification. Clotting index was calculated as fol-
lows: clotting time [sec.]−1 × 100.
calibrated thrombin and FXa generation
Thrombin generation was performed on a Fluoroskan 
Ascent FL Microplate Fluorometer and Luminometer 
(Thermo Fisher Scientific) by using a filter pair with exci-
tation at 390 nm and emission at 460 nm. To each well of a 
96-well plate containing 80 µl of eosinophils (250,000 cells) 
resuspended in plasma (10% rat/90% human), 20 µl of trigger 
solution (PBS, ADP, or collagen and/or phospholipids) was 
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added and incubated for 10 min at 37°C. End concentra-
tion of ADP (Roche) was 40 µM. Then, 20 µl of recalcifica-
tion solution containing a fluorogenic substrate for thrombin 
(Z-Gly-Gly-Arg) was automatically added. α2-Macroglobu-
lin–thrombin was used separately for calibration according 
to the manufacturer’s specifications (Thermo Fisher Scien-
tific). FXa generation was performed equally but with the 
fluorogenic substrate Pefafluor FXa (Loxo GMBH) and 
a filter pair with excitation at 340 nm and emission at 440 
nm. When indicated, eosinophils were pretreated with 1 µM 
baicalein (EMD Millipore) or DMSO control and 40 µg/
ml anti–mouse coagulation factor III/TF antibody (AF3178; 
R&D Systems) or isotype control (normal goat IgG; 
AB-108-C; R&D Systems) for 1 h at 37°C before stimulation. 
For thrombin generation with platelet-rich plasma (PRP) or 
platelet-poor plasma (PPP), PRP reagent (final concentration 
0.5 pM TF; cat. no. TS42.00; Thrombinoscope) or PPP re-
agent (final concentration 5 pM TF and 4 mM phospholipids; 
cat. no. TS30.00; Thrombinoscope) was added according to 
the manufacturer’s specifications. Data were evaluated using 
Thrombinoscope 5.0 software.
calcium signaling
500,000 cells were stained with 6  µM Fluo-3 (Invitrogen) 
and 12 µM FuraRed (Invitrogen) in 200 µl of staining buffer 
(RPMI; 10 mM Hepes and 2% FCS) for 45 min at 37°C with 
gentle agitation. Cells were subsequently washed twice in 
Ca2+-free Tyrode’s buffer (134 mM NaCl, 12 mM NaHCO3, 
2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM 
Hepes, 5 mM Hepes, and 0.5% BSA, pH 7.4) and incubated 
for 20 min at room temperature in the dark. Where indicated, 
CaCl2 was added to a final concentration of 1 mM. Calcium 
signaling experiments were performed at room temperature 
with a Gallios flow cytometer (Beckman Coulter) record-
ing the Fluo-3/FuraRed ratio over time. Data were analyzed 
using FlowJo software (Tree Star). The reagents used were: 
BAP TA/AM and thapsigargin (EMD Millipore), tannic acid, 
and A23187 (Sigma-Aldrich).
antibodies
Rat anti–mouse SiglecF PE (E50-2440; BD), rabbit poly-
clonal anti–12-LO (ab23678; Abcam), rabbit anti–mouse 
TF (EPR8986; Abcam), polyclonal goat anti–mouse coagu-
lation factor III/TF antibody (no. AF3178; R&D Systems), 
goat anti–rabbit Cy5 or Cy3 (Dianova), anti–mouse CD11b 
PE/Cy7 (M1/70), anti–human CD16 FITC (3G8), anti–
mouse Ly6G FITC (1A8), anti–mouse CD41 PE or APC 
(MWReg30), anti–mouse CD115 PE or APC (AFS98), anti–
mouse CD45 APC/Cy7 (30-F11), and anti–mouse CD16/32 
(TruStain fcX) were used. Annexin V FITC and DAPI stain-
ing were purchased from BioLegend.
Facs and flow cytometry
Bone marrow was isolated from sacrificed WT mice, and 
blood was drawn from the IVC of anaesthetized mice using 
a syringe (23-G needle) containing 10% 0.1 M sodium ci-
trate. Red blood cells were gently lysed with ice-cold distilled 
water. Cells were pelleted and resuspended in buffer (1× PBS 
containing 0.5% BSA and 2  mM EDTA). After Fc recep-
tor blockade, cells were stained with antibodies as indicated. 
For intracellular staining of 12/15-LO in blood leukocytes, 
cells were fixed and permeabilized before staining using a 
intracellular staining kit (00-5523; eBioscience). FACS was 
performed on a MoFlo XDP cell sorter (Beckman Coulter), 
and flow cytometry was performed on a Gallios flow cytom-
eter (Beckman Coulter). Data were analyzed using FlowJo 
software. Platelet counts were recorded from citrated whole 
blood with an Adivia 120 cytometer (Siemens Healthcare).
Immunofluorescence microscopy
For microscopy, thrombi were only partially dissected from 
the vessels to increase stability during preparation of the his-
tological sections. Samples were embedded in Tissue-Tek op-
timal cutting temperature compound (Sakura), snap frozen, 
and stored at −80°C. 4-µm cryosections were fixated and per-
meabilized with ice-cold acetone and stored at −20°C until 
staining. Slides were stained with the indicated antibodies 
(dilution 1:100) and analyzed on an ECL IPSE Ni-U micro-
scope (Nikon). Pictures were processed using NIS-Elements 
software (BR4.0; Nikon). For quantification of eosinophils in 
mouse thrombi, we analyzed thrombi of three independent 
experiments (four slides per individual thrombus).
Isolation of platelets and generation of PrP and PPP
To avoid artificial platelet activation, blood was carefully 
drawn from the IVC of anaesthetized mice, using a syringe 
(23-G needle) containing 10% 0.1 M sodium citrate. To iso-
late platelets, a same volume of EDTA-Hepes-saline buffer 
(150 mM NaCl, 1 mM EDTA, and 10 mM Hepes) was added 
to the citrated blood, followed by two 20-min centrifugations 
at 50 g. Platelets were pelleted for 5 min at 300 g and resus-
pended in HBSA buffer (20 mM Hepes, 100 mM NaCl, and 
1 mg/ml BSA) for further analysis. PRP was generated out of 
citrated plasma by 10-min centrifugation at 50 g and diluted 
to 140 cells/nl with autologous plasma. PPP was generated by 
two 10-min centrifugations at 1,500 g.
Isolation of human eosinophils
Blood was drawn from healthy, nonatopic volunteers into sy-
ringes containing 10% 0.1  M citrate and was immediately 
processed. Cells were separated by Ficoll gradient centrifu-
gation (Lymphoflot no. 824012; Bio-Rad Laboratories) ac-
cording to the manufacturer’s specifications. From now on, 
all procedures described were performed at 4°C. The granu-
locyte-rich red pellet was subsequently lysed using ice-cold 
distilled water. Untouched eosinophils were isolated using a 
commercially available eosinophil isolation kit (130-092-010; 
Miltenyi Biotec) according to the manufacturer’s specifica-
tions. Purity of enriched eosinophils was evaluated by flow 
cytometry of side scatter and CD16 expression. Cells were 
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resuspended in RPMI medium containing 10% FCS and 
stimulated with ADP or baicalein for 30 min at 37°C. Then, 
cells were washed and resuspended in HBSA buffer, and cell 
lysates were generated by three repeated freeze-thaw cycles. 
Samples were stored at −80°C until further analysis.
Western blotting
Cells were washed twice with PBS and then lysed in radioim-
munoprecipitation assay (RIPA) buffer (50 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxy-
cholate, and 0.1% SDS) containing 1% protease/phosphatase 
inhibitor (P9599; Sigma-Aldrich) and 1 mM PMSF (Active 
Motif) for 30 min on ice. Aortas were rinsed three times with 
PBS containing 1,000 IU heparin, cut into little pieces, and 
digested in serum-free DMEM containing 2 mg/ml colla-
genase type 2 (Worthington Biochemical Corporation) for 
1 h at 37°C and then lysed in RIPA buffer for 30 min on 
ice. Protein content was assessed using a BCA Protein Assay 
kit (Thermo Fisher Scientific) according to the manufactur-
er’s specifications. Protein extracts were separated by SDS-
PAGE using a 10% SDS-polyacrylamide gel, transferred to 
a Trans-Blot Nitrocellulose membrane (Bio-Rad Laborato-
ries), and immunoblotted overnight in TBS-Tween contain-
ing 5% nonfat dry milk with the following antibodies: rabbit 
polyclonal anti–12-LO (ab23678; dilution 1:1,000; Abcam), 
mouse coagulation factor III/TF antibody (no. AF3178; di-
lution 1:200; R&D Systems), and rabbit anti–mouse β-actin 
(clone AC-74; dilution 1:1,000; Sigma-Aldrich). As a positive 
control for TF expression, lysates of LPS-treated RAW 264.7 
mouse macrophages were used.  As a positive control for 
12/15-LO, mouse-resident macrophages were isolated from 
the peritoneal cavity of C57BL/6 mice by lavage, plated in 
RPMI medium, and washed thoroughly after 1 h to remove 
any nonadherent cells. After overnight culture in RPMI me-
dium containing 10% FCS, cells were lysed in RIPA buffer 
and stored at −20°C until further analysis.
real-time Pcr analysis
RNA was isolated with peqGOLD TRIFast (peqlab), and 
500 ng of total RNA was reverse transcribed with human 
leukemia virus reverse transcription using the Gene Amp 
RNA PCR kit (Applied Biosystems) and oligo deoxythy-
midine primers. For quantitative RT-PCR after FACS, leu-
kocyte subpopulations were directly sorted into lysis buffer, 
and RNA isolation was performed with an RNeasy Mini 
kit (QIA GEN) including DNA digestion (DNase I; no. 
EN0521; Fermentas) according to the manufacturer’s spec-
ifications. Quantitative real-time PCR was performed using 
a LightCycler instrument and SYBR Green I kit (Roche). 
We normalized the ratio of mRNA expression of the gene 
of interest to the mRNA expression for housekeeping genes 
Actb or Gapdh (with comparable results); depicted if not oth-
erwise stated are the results for normalization to Actb (2−▵Ct). 
For detection of TF mRNA, two different primer pairs were 
used with comparable results; depicted in the paper are the 
results for primer pair 1. Used PCR primer sequences for 
mouse mRNA were: Actb forward, 5′-TGT CCA CCT TCC 
AGC AGA TGT-3′ and reverse, 5′-AGC TCA GTA ACA GTC 
CGC CTA GA-3′; Gapdh forward, 5′-CTA CAC TGA GGA 
CCA GGT TGT CT-3′ and reverse, 5′-CAG GAA ATG AGC 
TTG ACA AAG TT-3′; Alox5 forward, 5′-ATT GCC ATC 
CAG CTC AAC CA-3′ and reverse, 5′-ACT GGA ACG CAC 
CCA GAT TT-3′; Alox12 forward, 5′-CGC TGT TGC CAC 
CAT GAG AT-3′ and reverse, 5′-ATG AGC TGG GTC CGC 
GTTC-3′; Alox15 forward, 5′-CTC TCA AGG CCT GTT 
CAG GA-3′ and reverse, 5′-GTC CAT TGT CCC CAG AAC 
CT-3′; Ccr3 forward, 5′-ACT GGA CTC ATA AAG GAC TTA 
GCA-3′ and reverse, 5′-CCA TGA CCC CAG CTC TTT GA-
3′; Epx forward, 5′-CGC CTG GAT AGC CAG TAT CG-3′ 
and reverse, 5′-ATG GAA TCC TGC CGG TTC AG-3′; Si-
glecf forward, 5′-TCA GCC CTG AAA GTA GCA GC-3′ and 
reverse, 5′-TTT GGG TGT CTG GGA CTG TG-3′; F3 (co-
agulation factor III; TF) no. 1 forward, 5′-AGG ATG TAC 
CTG GGC CTAT-3′ and reverse, 5′-GGC TGT CCA AGG 
TTT GTG TC-3′; and F3 (coagulation factor III; TF) no. 2 
forward, 5′-GAA ACT GGA AAA ACA AGT GCT TCTT-3′ 
and reverse, 5′-CCA GGT CAC ATC CTT CAC GAT-3′. Used 
PCR primer sequences for human mRNA were: Alox15 for-
ward, 5′-GTG TCC ACT GGG GCC TCG CT-3′ and reverse, 
5′-GCG GCC CCA GAT ACT CCG GTA-3′; Alox5 forward, 
5′-GAC GTT CAC GGC CGA GGT GG-3′ and reverse, 5′-
AGC TGG CCG AAG TTG ACC GC-3′; Actb forward, 5′-
AGA AAA TCT GGC ACC ACA CC-3′ and reverse, 5′-TAG 
CAC AGC CTG GAT AGC AA-3′; and Gapdh forward, 5′-
TGA TGA CAT CAA GAA GGT GGT GAAG-3′ and reverse, 
5′-TCC TTG GAG GCC ATG TGG GCC AT-3′.
lipid extraction
10 ng 1,2-dimyristoyl-PE (DMPE) and 5 ng 15-HETE-d8 
were added to each sample before extraction as an internal 
standard. Hydroperoxides were reduced to the corresponding 
alcohol by adding 1 mM SnCl2 for 10 min at room tempera-
ture. Lipids were extracted by adding 1  M acetic acid and 
2-propanol hexane (2:20:30, vol/vol) to the sample at a ratio 
of 2.5 ml of solvent to 1 ml of sample by vortexing and then 
adding 2.5 ml of hexane. After vortexing and centrifugation 
at 1,500 rpm for 5 min, lipids were recovered in the upper 
hexane layer. Then, the samples were reextracted by the addi-
tion of an equal volume of hexane followed by further vor-
texing and centrifugation. The combined hexane layers were 
then dried under vacuum and analyzed for HETE-PEs and 
free eicosanoids using liquid chromatography tandem mass 
spectrometry (LC/MS/MS).
Hete-Pe quantitation using lc/Ms/Ms
Lipids were separated on a C18 Luna with a 3 µm or 150 
mm × 2 mm column (Phenomenex), using a gradient of 50–
100% B over 10 min followed by 30 min at 100% B (solvent 
A: methanol/acetonitrile/water, 1  mM ammonium acetate, 
60:20:20; solvent B: methanol, 1  mM ammonium acetate) 
2135JEM Vol. 214, No. 7
with a flow rate of 200 µl/min. Lipids were monitored using 
multiple reaction–monitoring mode. Transitions monitored 
were for parent ions of m/z 738.6, 764.6, 766.6, and 782.6 
[M−H]− fragmenting to daughter ions with m/z 219.2 (15-
HETE), 115.1 (5-HETE), or 179.1 (12-HETE). Standard 
curves were generated using internal standards (DMPE) and 
different synthetic primary standards. Products were quanti-
fied by LC/MS/MS electrospray ionization on an Applied 
Biosystems 4000 Q-Trap system. Acquisition of product ion 
spectra was triggered during elution of ions of interest, with 
the instrument operating in ion trap mode.
Free eicosanoid quantitation using lc/Ms/Ms
Lipids were separated on a C18 Spherisorb ODS2 column 
(150 × 4.6 mm; 5 µm particle; Waters Ltd) using a gradient of 
50–90% B over 30 min, followed by 5 min at 90% B (A, water/
acetonitrile/acetic acid, 75:25:0.1; B, methanol/acetonitrile/
acetic acid, 60:40:0.1) with a flow rate of 1 ml/min. Eicosa-
noid species were monitored with specific parent to daughter 
ion transitions in negative ion mode ([M−H]−) for HETEs 
(m/z 319.2) at 115 (5-HETE), 179.1 (12-HETE), 219 (15-
HETE), 155 (8-HETE), and 167 (11-HETE). 15-HETE-d8 
was monitored at m/z 327 to 226. Products were identified 
and quantified using primary standards, and internal standard 
runs in parallel under the same method conditions.
Quantification of externalized aminophospholipids
Externalization of PE and PS species in eosinophils was measured 
according as previously described (Thomas et al., 2014). In brief, 
cultured mouse eosinophils (4 × 106 per ml) were stimulated with 
ADP (40 µM) or the calcium ionophore A23187 (10 µM) and 
treated with EZ-link NHS-biotin or EZ-link sulfo-NHS-biotin 
(Thermo Fisher Scientific) for measuring total cellular lipids and 
external aminophospholipids, respectively, by LC/MS/MS.
Generation of liposomes
Liposomes used in the thrombin generation experiments 
contained 20% of the indicated oxidized or unoxidized phos-
pholipid species and 75% PAPC and 5% PAPS as carrier lip-
ids. Phospholipids were solved in methanol or chloroform 
and kept under a layer of argon on −80°C until usage.
Phospholipids used were: PAPS (110670; Avanti Polar 
Lipids, Inc.), 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosa-
tetraenoyl)-sn-glycero-3-phospho-l-serine PAPE (110638; 
Avanti Polar Lipids, Inc.), 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z- 
eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine 
PAPC (850459C; Avanti Polar Lipids, Inc.), and 1-hexade-
canoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3- 
phosphocholine 12-HETE-PE. Lipids were generated as pre-
viously described (Morgan et al., 2010).
Indicated phospholipids were added to PAPC/PAPS car-
rier lipids before solvent was evaporated under a gentle stream 
of Argon. Phospholipids were resuspended in HBSA buffer 
and generously vortexed. Then, liposomes were prepared by 10 
freeze-thaw cycles and kept on ice before performing the assay.
tail-bleeding assays
Two different tail-bleeding assays were performed as previ-
ously described (Liu et al., 2012; Rossaint et al., 2013) with 
minor modifications. In brief, mice were anaesthetized with 
ketamine (100 mg/kg body weight) and xylazine (20 mg/kg 
body weight) and placed under a heating lamp to maintain a 
constant body temperature of 37°C. A 3-mm (ca. 1–1.2-mm 
diameter) or 15-mm (ca. 2.2–2.5-mm diameter) piece of the 
tail tip was cut off with a sharp scalpel. The distal 2.5 cm of the 
bleeding tail was immediately dipped into a 50-ml tube filled 
with prewarmed 0.9% saline, and the time until cessation of 
blood flow for >5  s was recorded. If not otherwise stated, 
bleeding was monitored for 20 min in total to assess rebleed-
ings caused by lacking thrombus stability. The amount of lost 
blood was assessed by comparison of body weight (including 
tail tip) before and after bleeding (relative weight loss). Addi-
tionally, the collected blood was lysed, and OD575nm was re-
corded, indicating the hemoglobin content of the lost blood.
Injury-related venous thrombosis
Thrombosis was induced as described previously (Wang et al., 
2006) with minor modifications. In brief, mice (20–25 g body 
weight) were anaesthetized with ketamine (100 mg/kg body 
weight) and xylazine (20 mg/kg body weight) and placed 
under a heating lamp to maintain a constant body tempera-
ture of 37°C. A ventral midline incision was performed, and 
the intestines were gently put aside. The IVC was laid free 
carefully, and a filter paper (1 × 2 × 4 mm) soaked with 4% 
aqueous ferric chloride solution was placed on top of the ves-
sel. After 3-min incubation, the filter paper was removed, and 
the peritoneal cavity was thoroughly rinsed with prewarmed 
0.9% saline. After another 30 min, mice were sacrificed, blood 
was taken by cardiac puncture, and the vena cava contain-
ing the thrombus was removed. The clot was dissected free 
from the vessel and prepared under a microscope for further 
analysis. Wet thrombus weight was measured using a precision 
balance (Sartorius R16P) after removal of excess water.
Injury-related arterial thrombosis and intravital microscopy
Mouse platelets were isolated from whole blood, labeled with 
5-carboxy-flourescein diacetate succinimidyl ester, and ad-
justed to a final concentration of 150 × 106 platelets/250 µl. 
Mice were anesthetized (Medetomidin, 0.5 mg/kg body 
weight; Midazolam, 5 mg/kg body weight; and Fentanyl, 0.05 
mg/kg body weight), and the platelet suspension was injected 
i.v. via a jugular vein catheter. The contralateral carotid artery 
was prepared under a dissecting microscope (Stemi 2000-
CS; ZEI SS), and a filter paper (1 × 2 × 4 mm) presoaked 
in 10% FeCl3 solution was placed on top of the vessel. After 
3-min incubation, the filter paper was removed, and dynamic 
thrombus formation was recorded over time using a high-
speed wide-field fluorescence microscope (BX51WI; Olym-
pus) equipped with a long-distance condenser and a 20× (NA 
0.95) water immersion objective, a monochromator (MT 20; 
Olympus), and a charge-coupled device camera (ORCA-ER; 
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Hamamatsu Photonics). For image acquisition and analysis, a 
computer (Dell) with Cell^R software (Olympus) was used.
IVc flow restriction model
The IVC flow restriction model was previously described in 
detail (von Brühl et al., 2012). In brief, a median laparotomy 
was performed, and the IVC was exposed by atraumatic sur-
gery. We positioned a space holder (FloppyR II Guide Wire 
0.014 in [0.36 mm]; Guidant Corporation) on the outside 
of the vessel and placed a permanent narrowing ligature (8.0 
monofil polypropylene filament, Premilene; Braun) exactly 
below the left renal vein. Subsequently, the wire was removed 
to avoid complete vessel occlusion. Side branches were not 
ligated or manipulated. Flow velocity was determined imme-
diately after the flow restriction (Cap-Image 7.1). Because we 
wanted to rule out endothelial injury as a trigger for venous 
thrombosis, all mice with bleedings or any injury of the IVC 
during surgery were excluded from further analysis. There 
was no difference in the exclusion rate across the different 
experimental groups. The median laparotomy was immedi-
ately sutured by a 7.0 polypropylene suture (Ethicon). For 
weight measurement, the vessel was excised just below the 
renal veins and proximal to the confluence of the common 
iliac veins. After the restriction procedure, the blood flow ve-
locity was reduced by ∼80% (Fig. 1 B). The shear stress was 
0.144 dyne/cm2 ± 0.02 SEM before the flow restriction and 
0.072 dyne/cm2 ± 0.017 SEM after the procedure in the IVC 
close to the site of ligation. Sham experiments consisted of 
preparation of the IVC and placement of the filament under 
the vessel without ligation.
depletion of platelets and eosinophils 
and baicalein treatment
For depletion of eosinophils, 20 µg of purified rat anti–
mouse SiglecF (E50-2440; BD) or isotype rat IgG2a (BD) 
in 100  µl of sterile PBS was injected into the lateral tail 
vein. Experiments were performed 6 h after injection. For 
depletion of platelets, anti–platelet antibody (6A6-IgG2a; 
0.2 µg/g body weight) or isotope IgG2a was injected 
into the lateral tail vein (both antibodies were provided 
by F. Nimmerjahn, Friedrich-Alexander-University Er-
langen-Nürnberg, Erlangen, Germany). Experiments were 
performed 1  h after injection. Depletion of platelets and 
eosinophils was evaluated by an Advia hemocytometer or 
Gallios flow cytometer (Beckman Coulter), respectively, in 
separate experiments after the indicated time to avoid any 
interference with the in vivo assays by the vascular injury. 
For inhibition of 12/15-LO in vivo, 10 µg/g body weight 
baicalein or DMSO control in 200 µl PBS was injected in-
traperitoneal two times within 24 h. Experiments were per-
formed 1 h after last injection.
elI sas
Mouse blood was drawn into syringes containing 10% 
0.1 M citrate and immediately put on ice. Plasma was ob-
tained by 10-min centrifugation (3,000  g) and stored at 
−80°C until analysis. The following ELI SA kits were used: 
Mouse TAT Complex ELI SA kit (EMT1020-1; Assaypro) 
and Human ECP ELI SA kit (SK00128-01; Aviscera Bio-
science). ELI SAs were performed according to the manu-
facturer’s specifications.
statistics
Data are shown as means ± SEM. Group mean values from 
in vivo experiments were compared by unpaired, two-tailed 
Student’s t test, and in vitro experiments were analyzed using 
one-way ANO VA (Bonferroni correction for multiple com-
parison). If not otherwise indicated, the data shown are rep-
resentative of at least three experiments producing similar 
results. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
online supplemental material
Table S1 shows a summary of the variables of the study co-
hort and includes additional data on the distribution of eo-
sinophils within thrombi. Fig. S1 shows immunofluorescence 
imaging data of mouse thrombi. Fig. S2 includes data on the 
parameters of platelet function and plasmatic coagulation in 
ΔdblGATA1 mice. Fig. S3 includes data on the used gating 
strategies, 12/15-LO expression in the vascular wall, and the 
procoagulatory potential of eosinophils. Fig. S4 shows addi-
tional data about parameters of platelet function and plas-
matic coagulation in Alox15−/− mice.
acknoWledGMents
We thank Alexandra Klej and Cornelia Stoll for excellent technical assistance and 
David Slatter for help during coagulation assays and generation of liposomes. 6A6 
antibody was a kind gift from Falk Nimmerjahn.
This study was supported the Deutsche Forschungsgemeinschaft (grant 
CRC1181 to G. Krönke and G. Schett as well as grant ZA428/8-1 to A. Zarbock), the 
Else-Kröner Fresenius Stiftung (2013_A274 to G. Krönke), the European Union Euro-
pean Research Council (grant StG 640087–SOS to G. Krönke), the National Institutes 
of Health (grant HL065228 to J.J. Lee.), as well as the ELAN-fond of the University 
Erlangen-Nuremberg (grant 12-09-24-1-Uderhardt to S. Uderhardt). M. Mayr is a 
senior fellow of the British Heart Foundation. The study was supported by the Na-
tional Institute for Health Research Biomedical Research Center based at Guy’s and 
St Thomas’ National Health Service Foundation Trust and King’s College London in 
partnership with King’s College Hospital. Funding from the Wellcome Trust (grant 
094143/Z/10/Z) and British Heart Foundation (grant RG/12/11/29815) program 
grants is gratefully acknowledged (V.B. O’Donnell and P.W. Collins). S. Kiechl, J. Willeit, 
P. Santer, and M. Mayr are supported by an excellence initiative (Competence Centers 
for Excellent Technologies) of the Austrian Research Promotion Agency Forschungs-
förderungsgesellschaft Research Center of Excellence in Vascular Ageing, Tyrol 
(K-Project no. 843536) funded by the BMV IT, BMW FW, and Wirtschaftsagentur Wien 
and Standortagentur Tirol.
The authors declare no competing financial interests.
Author contributions: S. Uderhardt designed the study, performed experi-
ments, interpreted data, and wrote the manuscript. J.A. Ackermann, T. Fillep, V.J. 
Hammond, M. Biburger, K. Stark, J. Rossaint, and C. Heim designed and performed 
experiments and interpreted data. S. Kiechl, J. Willeit, P. Santer, M. Mayr, B. Dietel, D. 
Raaz-Schrauder, C. Ay, T. Gremmel, and J. Thaler collected patient samples and analyzed 
and interpreted data. M. Mayr provided proteomics measurement and interpreted 
data. A. Zarbock, D. Mielenz, M. Herrmann, P.W. Collins, G. Schabbauer, D. Voehringer, 
2137JEM Vol. 214, No. 7
N. Mackman, S. Massberg, M. Rauh, K.R. Zellner, J.L. Nadler, and G. Schett helped to 
design the study and provided important technical input. J.J. Lee and V.B. O’Donnell 
helped to design the study and wrote the manuscript. G. Krönke designed the study 
and wrote the manuscript. All authors read and commented on the manuscript.
Submitted: 11 July 2016
Revised: 12 February 2017
Accepted: 19 April 2017
reFerences
Ames, P.R., M. Margaglione, S. Mackie, and J.D. Alves. 2010. Eosinophilia 
and thrombophilia in churg strauss syndrome: a clinical and pathogenetic 
overview. Clin. Appl. Thromb. Hemost. 16:628–636. http ://dx .doi .org /10 
.1177 /1076029609348647
Assarsson, E., M. Lundberg, G. Holmquist, J. Björkesten, S.B. Thorsen, 
D. Ekman, A. Eriksson, E. Rennel Dickens, S. Ohlsson, G. Edfeldt, et 
al. 2014. Homogenous 96-plex PEA immunoassay exhibiting high 
sensitivity, specificity, and excellent scalability. PLoS One. 9:e95192. http 
://dx .doi .org /10 .1371 /journal .pone .0095192
Bergmeier, W., C. Weidinger, I. Zee, and S. Feske. 2013. Emerging roles 
of store-operated Ca2+ entry through STIM and ORAI proteins in 
immunity, hemostasis and cancer. Channels (Austin). 7:379–391. http ://
dx .doi .org /10 .4161 /chan .24302
Bouchard, B.A., K.G. Mann, and S. Butenas. 2010. No evidence for tissue 
factor on platelets. Blood. 116:854–855. http ://dx .doi .org /10 .1182 /
blood -2010 -05 -285627
Clark, S.R., C.P. Thomas, V.J. Hammond, M. Aldrovandi, G.W. Wilkinson, 
K.W. Hart, R.C. Murphy, P.W. Collins, and V.B. O’Donnell. 2013. 
Characterization of platelet aminophospholipid externalization reveals 
fatty acids as molecular determinants that regulate coagulation. Proc. 
Natl. Acad. Sci. USA. 110:5875–5880. http ://dx .doi .org /10 .1073 /pnas 
.1222419110
Cole, B.K., M.A. Morris, W.J. Grzesik, K.A. Leone, and J.L. Nadler. 2012. 
Adipose tissue-specific deletion of 12/15-lipoxygenase protects mice 
from the consequences of a high-fat diet. Mediators Inflamm. 2012:851798. 
http ://dx .doi .org /10 .1155 /2012 /851798
Cyrus, T., D. Praticò, L. Zhao, J.L. Witztum, D.J. Rader, J. Rokach, G.A. 
FitzGerald, and C.D. Funk. 2001. Absence of 12/15-lipoxygenase 
expression decreases lipid peroxidation and atherogenesis in 
apolipoprotein e-deficient mice. Circulation. 103:2277–2282. http ://dx 
.doi .org /10 .1161 /01 .CIR .103 .18 .2277
Doyle, A.D., E.A. Jacobsen, S.I. Ochkur, L. Willetts, K. Shim, J. Neely, J. 
Kloeber, W.E. Lesuer, R.S. Pero, P. Lacy, et al. 2013. Homologous 
recombination into the eosinophil peroxidase locus generates a strain 
of mice expressing Cre recombinase exclusively in eosinophils. J. Leukoc. 
Biol. 94:17–24. http ://dx .doi .org /10 .1189 /jlb .0213089
Dyer, K.D., J.M. Moser, M. Czapiga, S.J. Siegel, C.M. Percopo, and H.F. 
Rosenberg. 2008. Functionally competent eosinophils differentiated 
ex vivo in high purity from normal mouse bone marrow. J. Immunol. 
181:4004–4009. http ://dx .doi .org /10 .4049 /jimmunol .181 .6 .4004
Engelmann, B., and S. Massberg. 2013. Thrombosis as an intravascular effector 
of innate immunity. Nat. Rev. Immunol. 13:34–45. http ://dx .doi .org /10 
.1038 /nri3345
Flaumenhaft, R. 2014. Thrombus formation reimagined. Blood. 124:1697–
1698. http ://dx .doi .org /10 .1182 /blood -2014 -06 -579656
Heredia, J.E., L. Mukundan, F.M. Chen, A.A. Mueller, R.C. Deo, R.M. 
Locksley, T.A. Rando, and A. Chawla. 2013. Type 2 innate signals 
stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. 
Cell. 153:376–388. http ://dx .doi .org /10 .1016 /j .cell .2013 .02 .053
Jacobsen, E.A., R.A. Helmers, J.J. Lee, and N.A. Lee. 2012. The expanding 
role(s) of eosinophils in health and disease. Blood. 120:3882–3890. http 
://dx .doi .org /10 .1182 /blood -2012 -06 -330845
Kiechl, S., and J. Willeit. 1999a. The natural course of atherosclerosis. Part I: 
incidence and progression. Arterioscler. Thromb. Vasc. Biol. 19:1484–1490. 
http ://dx .doi .org /10 .1161 /01 .ATV .19 .6 .1484
Kiechl, S., and J. Willeit. Bruneck Study Group. 1999b. The natural course of 
atherosclerosis. Part II: vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 
19:1491–1498. http ://dx .doi .org /10 .1161 /01 .ATV .19 .6 .1491
Kiechl, S., E. Lorenz, M. Reindl, C.J. Wiedermann, F. Oberhollenzer, 
E. Bonora, J. Willeit, and D.A. Schwartz. 2002. Toll-like receptor 4 
polymorphisms and atherogenesis. N. Engl. J. Med. 347:185–192. http ://
dx .doi .org /10 .1056 /NEJMoa012673
Kiechl, S., G. Schett, J. Schwaiger, K. Seppi, P. Eder, G. Egger, P. Santer, A. 
Mayr, Q. Xu, and J. Willeit. 2007. Soluble receptor activator of nuclear 
factor-κB ligand and risk for cardiovascular disease. Circulation. 116:385–
391. http ://dx .doi .org /10 .1161 /CIR CUL ATI ONA HA .106 .686774
Kiechl, S., J. Wittmann, A. Giaccari, M. Knoflach, P. Willeit, A. Bozec, A.R. 
Moschen, G. Muscogiuri, G.P. Sorice, T. Kireva, et al. 2013. Blockade of 
receptor activator of nuclear factor-κB (RAN KL) signaling improves 
hepatic insulin resistance and prevents development of diabetes mellitus. 
Nat. Med. 19:358–363. http ://dx .doi .org /10 .1038 /nm .3084
Kuhn, H., S. Banthiya, and K. van Leyen. 2015. Mammalian lipoxygenases 
and their biological relevance. Biochim. Biophys. Acta. 1851:308–330. http 
://dx .doi .org /10 .1016 /j .bbalip .2014 .10 .002
Kühn, H., and V.B. O’Donnell. 2006. Inflammation and immune regulation 
by 12/15-lipoxygenases. Prog. Lipid Res. 45:334–356. http ://dx .doi .org 
/10 .1016 /j .plipres .2006 .02 .003
Kunzelmann, K., B. Nilius, G. Owsianik, R. Schreiber, J. Ousingsawat, L. 
Sirianant, P. Wanitchakool, E.M. Bevers, and J.W. Heemskerk. 2014. 
Molecular functions of anoctamin 6 (TMEM16F): a chloride channel, 
cation channel, or phospholipid scramblase? Pflugers Arch. 466:407–414. 
http ://dx .doi .org /10 .1007 /s00424 -013 -1305 -1
Lee, J.J., D. Dimina, M.P. Macias, S.I. Ochkur, M.P. McGarry, K.R. O’Neill, 
C. Protheroe, R. Pero, T. Nguyen, S.A. Cormier, et al. 2004. Defining a 
link with asthma in mice congenitally deficient in eosinophils. Science. 
305:1773–1776. http ://dx .doi .org /10 .1126 /science .1099472
Lee, J.J., E.A. Jacobsen, M.P. McGarry, R.P. Schleimer, and N.A. Lee. 2010. 
Eosinophils in health and disease: the LIAR hypothesis. Clin. Exp. Allergy. 
40:563–575. http ://dx .doi .org /10 .1111 /j .1365 -2222 .2010 .03484 .x
Liu, Y., N.L. Jennings, A.M. Dart, and X.J. Du. 2012. Standardizing a simpler, 
more sensitive and accurate tail bleeding assay in mice. World J. Exp. Med. 
2:30–36. http ://dx .doi .org /10 .5493 /wjem .v2 .i2 .30
Mackman, N. 2004. Role of tissue factor in hemostasis, thrombosis, and 
vascular development. Arterioscler. Thromb. Vasc. Biol. 24:1015–1022. http 
://dx .doi .org /10 .1161 /01 .ATV .0000130465 .23430 .74
McCarty, O.J., N. Tien, B.S. Bochner, and K. Konstantopoulos. 2003. 
Exogenous eosinophil activation converts PSGL-1-dependent binding 
to CD18-dependent stable adhesion to platelets in shear flow. Am. J. 
Physiol. Cell Physiol. 284:C1223–C1234. http ://dx .doi .org /10 .1152 /
ajpcell .00403 .2002
Moosbauer, C., E. Morgenstern, S.L. Cuvelier, D. Manukyan, K. Bidzhekov, S. 
Albrecht, P. Lohse, K.D. Patel, and B. Engelmann. 2007. Eosinophils are a 
major intravascular location for tissue factor storage and exposure. Blood. 
109:995–1002. http ://dx .doi .org /10 .1182 /blood -2006 -02 -004945
Morgan, A.H., V.J. Hammond, L. Morgan, C.P. Thomas, K.A. Tallman, Y.R. 
Garcia-Diaz, C. McGuigan, M. Serpi, N.A. Porter, R.C. Murphy, and V.B. 
O’Donnell. 2010. Quantitative assays for esterified oxylipins generated 
by immune cells. Nat. Protoc. 5:1919–1931. http ://dx .doi .org /10 .1038 /
nprot .2010 .162
Eosinophils promote plasmatic coagulation | Uderhardt et al.2138
Nemerson, Y. 1968. The phospholipid requirement of tissue factor in blood 
coagulation. J. Clin. Invest. 47:72–80. http ://dx .doi .org /10 .1172 /
JCI105716
O’Donnell, V.B., R.C. Murphy, and S.P. Watson. 2014. Platelet lipidomics: 
modern day perspective on lipid discovery and characterization in 
platelets. Circ. Res. 114:1185–1203. http ://dx .doi .org /10 .1161 /CIR 
CRE SAHA .114 .301597
Riegger, J., R.A. Byrne, M. Joner, S. Chandraratne, A.H. Gershlick, J.M. Ten 
Berg, T. Adriaenssens, G. Guagliumi, T.C. Godschalk, F.J. Neumann, et 
al. Prevention of Late Stent Thrombosis by an Interdisciplinary Global 
European Effort (PRE STI GE) Investigators. 2016. Histopathological 
evaluation of thrombus in patients presenting with stent thrombosis. 
A multicenter European study: a report of the prevention of late stent 
thrombosis by an interdisciplinary global European effort consortium. 
Eur. Heart J. 37:1538–1549. http ://dx .doi .org /10 .1093 /eurheartj /
ehv419
Rossaint, J., D. Vestweber, and A. Zarbock. 2013. GDF-15 prevents platelet 
integrin activation and thrombus formation. J. Thromb. Haemost. 11:335–
344. http ://dx .doi .org /10 .1111 /jth .12100
Rothenberg, M.E., and S.P. Hogan. 2006. The eosinophil. Annu. Rev. 
Immunol. 24:147–174. http ://dx .doi .org /10 .1146 /annurev .immunol .24 
.021605 .090720
Stegemann, C., R. Pechlaner, P. Willeit, S.R. Langley, M. Mangino, U. Mayr, 
C. Menni, A. Moayyeri, P. Santer, G. Rungger, et al. 2014. Lipidomics 
profiling and risk of cardiovascular disease in the prospective population-
based Bruneck study. Circulation. 129:1821–1831. http ://dx .doi .org /10 
.1161 /CIR CUL ATI ONA HA .113 .002500
Stevens, G., M. Mascarenhas, and C. Mathers. 2009. Global health risks: 
progress and challenges. Bull. World Health Organ. 87:646. http ://dx .doi 
.org /10 .2471 /BLT .09 .070565
Suzuki, J., M. Umeda, P.J. Sims, and S. Nagata. 2010. Calcium-dependent 
phospholipid scrambling by TMEM16F. Nature. 468:834–838. http ://dx 
.doi .org /10 .1038 /nature09583
Tani, Y., Y. Isobe, Y. Imoto, E. Segi-Nishida, Y. Sugimoto, H. Arai, and M. Arita. 
2014. Eosinophils control the resolution of inflammation and draining 
lymph node hypertrophy through the proresolving mediators and 
CXCL13 pathway in mice. FAS EB J. 28:4036–4043. http ://dx .doi .org 
/10 .1096 /fj .14 -251132
Thomas, C.P., L.T. Morgan, B.H. Maskrey, R.C. Murphy, H. Kühn, S.L. 
Hazen, A.H. Goodall, H.A. Hamali, P.W. Collins, and V.B. O’Donnell. 
2010. Phospholipid-esterified eicosanoids are generated in agonist-
activated human platelets and enhance tissue factor-dependent thrombin 
generation. J. Biol. Chem. 285:6891–6903. http ://dx .doi .org /10 .1074 /
jbc .M109 .078428
Thomas, C.P., S.R. Clark, V.J. Hammond, M. Aldrovandi, P.W. Collins, and V.B. 
O’Donnell. 2014. Identification and quantification of aminophospholipid 
molecular species on the surface of apoptotic and activated cells. Nat. 
Protoc. 9:51–63. http ://dx .doi .org /10 .1038 /nprot .2013 .163
Tian, Y., R. Schreiber, and K. Kunzelmann. 2012. Anoctamins are a family of 
Ca2+-activated Cl− channels. J. Cell Sci. 125:4991–4998. http ://dx .doi 
.org /10 .1242 /jcs .109553
Todd, S., C. Hemmaway, and Z. Nagy. 2014. Catastrophic thrombosis in 
idiopathic hypereosinophilic syndrome. Br. J. Haematol. 165:425. http ://
dx .doi .org /10 .1111 /bjh .12729
Uderhardt, S., and G. Krönke. 2012. 12/15-lipoxygenase during the 
regulation of inflammation, immunity, and self-tolerance. J. Mol. Med. 
(Berl.). 90:1247–1256. http ://dx .doi .org /10 .1007 /s00109 -012 -0954 -4
von Brühl, M.L., K. Stark, A. Steinhart, S. Chandraratne, I. Konrad, M. Lorenz, 
A. Khandoga, A. Tirniceriu, R. Coletti, M. Köllnberger, et al. 2012. 
Monocytes, neutrophils, and platelets cooperate to initiate and propagate 
venous thrombosis in mice in vivo. J. Exp. Med. 209:819–835. http ://dx 
.doi .org /10 .1084 /jem .20112322
Wang, X., P.L. Smith, M.Y. Hsu, M.L. Ogletree, and W.A. Schumacher. 
2006. Murine model of ferric chloride-induced vena cava thrombosis: 
evidence for effect of potato carboxypeptidase inhibitor. J. Thromb. 
Haemost. 4:403–410. http ://dx .doi .org /10 .1111 /j .1538 -7836 .2006 
.01703 .x
Willeit, J., S. Kiechl, F. Oberhollenzer, G. Rungger, G. Egger, E. Bonora, 
M. Mitterer, and M. Muggeo. 2000. Distinct risk profiles of early and 
advanced atherosclerosis: prospective results from the Bruneck Study. 
Arterioscler. Thromb. Vasc. Biol. 20:529–537. http ://dx .doi .org /10 .1161 /01 
.ATV .20 .2 .529
Wolberg, A.S. 2007. Thrombin generation and fibrin clot structure. Blood Rev. 
21:131–142. http ://dx .doi .org /10 .1016 /j .blre .2006 .11 .001
Yang, H., A. Kim, T. David, D. Palmer, T. Jin, J. Tien, F. Huang, T. Cheng, 
S.R. Coughlin, Y.N. Jan, and L.Y. Jan. 2012. TMEM16F forms a Ca2+-
activated cation channel required for lipid scrambling in platelets during 
blood coagulation. Cell. 151:111–122. http ://dx .doi .org /10 .1016 /j .cell 
.2012 .07 .036
Yu, C., A.B. Cantor, H. Yang, C. Browne, R.A. Wells, Y. Fujiwara, and S.H. 
Orkin. 2002. Targeted deletion of a high-affinity GATA-binding site in 
the GATA-1 promoter leads to selective loss of the eosinophil lineage 
in vivo. J. Exp. Med. 195:1387–1395. http ://dx .doi .org /10 .1084 /jem 
.20020656
